Andrew Gianoukakis is an Endocrinology/Metabolic physician affiliated with UCLA Medical Center. OpenAlex indexes 109 publications with 4,765 citations (h-index 29).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
21840 Normandie Ave
Ste. 700
Torrance, CA 905022047
Telephone
310-222-5183Registry record last updated 9 Jul 2019.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Eisai Inc.Program year20252 payments
- Amgen Inc.Program year20241 payment
- Eisai Inc.Program year20233 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Hormonal (systemic)
46.5%l-Thyroxine46.5%Levothyroxine Sodium100%Part D<11 patientsCardiovascular
27.9%Statin27.9%Pravastatin Sodium100%Part D<11 patientsMetabolism & gastrointestinal
25.6%SGLT2 inhibitor25.6%Jardiance100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2002–2010 per NIH RePORTER. The latest:
- THYROCYTES EXPRESS INFLAMMATORY MEDIATORS
Lundquist Institute for Biomedical Innovation at Harbor-Ucla Medical Center
FY2010$199,047M01RR000425 - THYROCYTES EXPRESS INFLAMMATORY MEDIATORS
Lundquist Institute for Biomedical Innovation at Harbor-Ucla Medical Center
FY2009$82,837M01RR000425 - THYROCYTES EXPRESS INFLAMMATORY MEDIATORS
Lundquist Institute for Biomedical Innovation at Harbor-Ucla Medical Center
FY2009$1,117M01RR000425
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statement
The Lancet Diabetes & Endocrinology
2025 - Influence of Thyroglobulin Autoantibodies on Thyroglobulin Levels Measured by Different Methodologies: IMA, LC-MS/MS, and RIA
The Journal of Clinical Endocrinology & Metabolism
2024 - Thyroglobulin Cutoff Values for Detecting Excellent Response to Therapy in Patients With Differentiated Thyroid Cancer
Journal of the Endocrine Society
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Anthony Bohan, MD, JD
UCLA Medical Center
Ira Lesser, MD
UCLA Medical Center
Darryl Sue, MD
UCLA Medical Center
Kenneth Zangwill, MD
UCLA Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”